Chronic hepatitis B virus (HBV) infection is a common cause of liver disease globally, with a
disproportionately high burden in South-East Asia. Vaccines and nucleoside or nucleotide …

Representatives from academia, industry, regulatory agencies, and patient groups
convened in March 2019 with the primary goal of developing agreement on chronic hepatitis …

Current antiviral therapies, such as pegylated interferon-α and nucleos (t) ide analogues,
effectively improve the quality of life of patients with chronic hepatitis B. However, they can …

Hepatitis B virus (HBV) infection, although preventable by vaccination, remains a global
health problem and a major cause of chronic liver disease. Although current treatment …

Background & Aims HBV causes hepatocellular carcinoma (HCC). While it was recently
shown that the ability of HBV X protein (HBx) to impair the Smc5/6 (structural maintenance of …

Chronic hepatitis B virus (HBV) infection is a substantial global public health problem.
Despite the availability of a protective vaccine for more than 3 decades, the prevalence of …

The hepatitis B virus (HBV) is a major cause of cirrhosis and hepatocellular carcinoma
worldwide. Despite an effective vaccine, the prevalence of chronic infection remains high …

Neddylation is one type of protein post‐translational modification by conjugating a ubiquitin‐
like protein neural precursor cell‐expressed developmentally downregulated protein 8 to …

Despite the availability of a prophylactic vaccine, chronic hepatitis B (CHB) caused by the
hepatitis B virus (HBV) is a major health problem affecting an estimated 292 million people …

Chronic infection with HBV is a major cause of advanced liver disease and hepatocellular
carcinoma. Nucleos (t) ide analogues effectively control HBV replication but viral cure is …